ArticleLiver international : official journal of the International Association for the Study of the Liver2025
Mortality and Cancer in Offspring of Mothers With Biopsy-Proven MASLD During Pregnancy: A Nationwide Cohort Study.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Autoimmune disease in offspring of mothers with metabolic dysfunction-associated steatotic liver disease (MASLD): a nationwide cohort study.Scientific reports · 2026Article
- Higher Risk of Serious Infection in Offspring of Mothers With Biopsy-Proven MASLD: A Nationwide Cohort Study.United European gastroenterology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND &
aimsHealth-related outcomes through early adulthood among offspring prenatally exposed to maternal metabolic dysfunction-associated steatotic liver disease (MASLD) are insufficiently investigated. We aimed to study the risk of mortality and cancer in such offspring.
methodsThis nationwide cohort study included all singleton live born offspring with prenatal exposure to maternal biopsy-proven MASLD (1992-2017; N = 239) in Sweden. MASLD offspring were matched with up to five reference offspring (N = 1131) of mothers without known MASLD by maternal age at delivery, calendar year of delivery, and parity. We used a multivariable Cox proportional hazard model to calculate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for mortality and cancer up until 31 December 2021. For mortality, we stratified by maternal MASLD severity (simple steatosis alone vs. severe MASLD comprising steatohepatitis, liver fibrosis or cirrhosis).
resultsOver a median follow-up of 16.9 years, two deaths occurred in offspring prenatally exposed to maternal MASLD (IR 0.5/1000 person-years, 95% CI 0.1-1.8) and seven deaths in reference offspring (IR 0.4/1000 person-years, 95% CI 0.1-0.8), which corresponded to an aHR of 1.78 (95% CI 0.27-11.97). Higher disease severity was not associated with an increased risk of death. We observed few cancer events with similar IR/1000 person-years (0.2 [95% CI 0.0-1.4] vs. 0.3 [0.1-0.6] in reference offspring), which corresponded to an aHR of 0.64 (95% CI 0.07-5.95).
conclusionsWe found no evidence that prenatal exposure to maternal MASLD affects the risk of death or cancer through early adulthood but larger studies are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.